Association of Serum Levels of Pentraxin-3, M-ficolin, and Surfactant Protein A with the Severity of Ischemic Stroke
,
Abstract
Stroke is one of the most leading causes of death and disability in the world. Complement system activation contributes to pathogenesis and neuronal damage following stroke. There are no defined biological serum markers to determine the severity of stroke in acute phases. The purpose of current study was to determine the association of three complement activators, namely Pentraxin-3 (PTX3),M-ficolin, and Surfactant protein A (SPA) with the severity of ischemic stroke. This cross-sectional study was done on 82 patients diagnosed with ischemic stroke at 24-96 hours of initiation of the clinical symptoms during 2014-2015. The serum levels of PTX3, M-ficolin, and SPA were measured by enzyme-linked immunosorbent assay ( ELISA). The patients were divided in three stroke severity groups according to modified National Institute of Health Stroke Scale mNIHSS. The results showed that the more severity of the stroke was, the higher serum levels of three evaluated molecules (p<0.001) were. The correlation of serum level of PTX3, M-ficolin, and SPA with stroke severity was 0.732, 0.736, and 0.731, respectively. There is a strong association between serum levels of PTX3, M-ficolin, and SPA with the severity of ischemic stroke. Clinically, such association may be considered to evaluate the severity of the ischemic stroke.
1. Willey JZ, Demmer RT, Takayama H, Colombo PC, Lazar RM. Cerebrovascular disease in the era of left ventricular assist devices with continuous flow: risk factors, diagnosis, and treatment. J Heart Lung Transplant 2014; 33(9):878-87.
2. Cervera A, Planas AM, Justicia C, Urra X, Jensenius JC, Torres F, et al. Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PloS one 2010; 5(2):e8433.
3. Pedersen ED, Waje-Andreassen U, Vedeler CA, Aamodt G, Mollnes TE. Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol 2004; 137(1):117-22.
4. Pedersen E, Løberg E, Vege E, Daha M, Maehlen J, Mollnes T. In situ deposition of complement in human acute brain ischaemia. Scand J Immunol 2009; 69(6):555-62.
5. Széplaki G, Szegedi R, Hirschberg K, Gombos T, Varga L, Karádi I, et al. Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. Atherosclerosis 2009; 204(1):315-20.
6. De Simoni MG, Rossi E, Storini C, Pizzimenti S, Echart C, Bergamaschini L. The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am J Pathol 2004; 164(5):1857-63.
7. Atkinson C, Zhu H, Qiao F, Varela JC, Yu J, Song H, et al. Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol 2006;177(10):7266-74.
8. Mocco J, Sughrue ME, Ducruet AF, Komotar RJ, Sosunov SA, Connolly Jr ES. The complement system: a potential target for stroke therapy. Adv Exp Med Biol 2006; 586:189-201.
9. Gesuete R, Storini C, Fantin A, Stravalaci M, Zanier ER, Orsini F, et al. Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol 2009; 66(3):332-42.
10. Ducruet AF, Hassid BG, Mack WJ, Sosunov SA, Otten ML, Fusco DJ, et al. C3a receptor modulation of granulocyte infiltration after murine focal cerebral ischemia is reperfusion dependent. J Cereb Blood Flow Metab 2008; 28(5):1048-58.
11. Cowell RM, Plane JM, Silverstein FS. Complement activation contributes to hypoxic-ischemic brain injury in neonatal rats. J Neurosci 2003; 23(28):9459-68.
12. Ying Fu, Qiang Liu, Josef Anrather, Fu-Dong Shi.Immune interventions in stroke. Nat Rev Neurol. 2015;11(9): 524–535.
13. Maas MB, Furie KL. Molecular biomarkers in stroke diagnosis and prognosis. Biomark Med 2009; 3(4):363-83.
14. Schäfer MK-H, Schwaeble WJ, Post C, Salvati P, Calabresi M, Sim RB, et al. Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J Immunol 2000;164(10):5446-52.
15. Nepomuceno R, Ruiz S, Park M, Tenner A. C1qRP is a heavily O-glycosylated cell surface protein involved in the regulation of phagocytic activity. J Immunol 1999;162(6):3583-9.
16. Ryu W-S, Kim CK, Kim BJ, Kim C, Lee S-H, Yoon BW.Pentraxin 3: a novel and independent prognostic marker in ischemic stroke. Atherosclerosis 2012; 220(2):581-6.
17. Kuraya M, Matsushita M, Endo Y, Thiel S, Fujita T.Expression of H-ficolin/Hakata antigen, mannose-binding lectin-associated serine protease (MASP)-1 and MASP-3 by human glioma cell line T98G. Int Immunol 2003;15(1):109-17.
18. Fust G, Munthe-Fog L, Illes Z, Szeplaki G, Molnar T, Pusch G, et al. Low ficolin-3 levels in early follow-up serum samples are associated with the severity and unfavorable outcome of acute ischemic stroke. J Neuroinflammation 2011; 8:185.
19. Kunes P, Holubcova Z, Kolackova M, Krejsek J.Pentraxin 3 (PTX 3): an endogenous modulator of the inflammatory response. Mediators Inflamm 2012;2012:920517.
20. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110(16):2349-54.
21. Khubchandani KR, SNYDER JM. Surfactant protein A (SP-A): the alveolus and beyond. FASEB J 2001;15(1):59-69.
22. Meyer BC, Lyden PD. The modified National Institutes of Health Stroke Scale: its time has come. Int J Stroke2009; 4(4):267-73.
23. Govan L, Langhorne P, Weir CJ. Categorizing stroke prognosis using different stroke scales. Stroke 2009;40(10):3396-9.
24. Rodriguez-Grande B, Swana M, Nguyen L, Englezou P, Maysami S, Allan SM, et al. The acute-phase protein PTX3 is an essential mediator of glial scar formation and resolution of brain edema after ischemic injury. J Cereb Blood Flow Metab 2014; 34(3):480-8.
25. Zangari R, Zanier E, Torgano G, Bersano A, Beretta S, Beghi E, et al. Early ficolin-1 is a sensitive prognostic marker for functional outcome in ischemic stroke. J Neuroinflammation 2016; 13(1):16.
26. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM.Associations of Pentraxin 3 With Cardiovascular Disease and All-Cause Death The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2009; 29(4):594-9.
27. Garlanda C, Bottazzi B, Moalli F, Deban L, Molla F, Latini R, et al. Pentraxins and atherosclerosis: the role of PTX3. Curr Pharm Des 2011; 17(1):38-46.
28. Bonacina F, Baragetti A, Catapano AL, Norata GD. Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases. Mediators Inflamm 2013;2013:725102.
29. Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 2010;20(2):35-40.
30. Rodriguez-Grande B, Varghese L, Molina-Holgado F,Rajkovic O, Garlanda C, Denes A, et al. Pentraxin 3 mediates neurogenesis and angiogenesis after cerebral ischaemia. J Neuroinflammation 2015; 12:15.
31. Osthoff M, Katan M, Fluri F, Schuetz P, Bingisser R, Kappos L, et al. Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. PloS one 2011;6(6):e21338.
32. VanGilder RL, Davidov DM, Stinehart KR, Huber JD, Turner RC, Wilson KS, et al. C-reactive protein and long- term ischemic stroke prognosis. J Clin Neurosci 2014;21(4):547-53.
33. Song IU, Kim JS, Kim YI, Lee KS, Jeong DS, Chung SW. Relationship between high-sensitivity C-reactive protein and clinical functional outcome after acute ischemic stroke in a Korean population. Cerebrovasc Dis 2009; 28(6):545-50.
| Files | ||
| Issue | Vol 16, No 2 (2017) | |
| Section | Original Article(s) | |
| Keywords | ||
| Ischemic stroke Pentraxin-3 M-ficolin Surfactant protein A | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
